SER — Serina Therapeutics Balance Sheet
0.000.00%
- $24.38m
- $29.21m
- $0.13m
Annual balance sheet for Serina Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Cash and Short Term Investments | 0.584 | 0.645 | 0.345 | 3.67 | 3.06 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.025 | 0.004 | 0.057 | — | — |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 2.23 | 2.45 | 0.754 | 5.68 | 6.08 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | — | — | — | 1.05 | 0.842 |
| Net Intangible Assets | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 3.15 | 3.24 | 12 | 6.72 | 6.95 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.97 | 10.1 | 5.91 | 2.37 | 3.56 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 15 | 20.5 | 6.5 | 6.08 | 6.99 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | -11.8 | -17.2 | 5.47 | 0.641 | -0.037 |
| Total Liabilities & Shareholders' Equity | 3.15 | 3.24 | 12 | 6.72 | 6.95 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |